These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 33622339)
1. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index. Trilling B; Brind'Amour A; Hamad R; Tremblay JF; Dubé P; Mitchell A; Sidéris L World J Surg Oncol; 2021 Feb; 19(1):60. PubMed ID: 33622339 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei]. Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280 [No Abstract] [Full Text] [Related]
3. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study. Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
5. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692 [TBL] [Abstract][Full Text] [Related]
6. Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept. Sgarbura O; Al Hosni M; Petruzziello A; Figueroa R; Khellaf L; Pissas MH; Carrère S; Nougaret S; Bibeau F; Quénet F Int J Hyperthermia; 2020; 37(1):585-591. PubMed ID: 32484014 [No Abstract] [Full Text] [Related]
7. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429 [TBL] [Abstract][Full Text] [Related]
8. Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs). Cusumano C; Carrere S; Bouillin A; Nougaret S; Khellaf L; Quénet F; Sgarbura O Surg Endosc; 2022 Jul; 36(7):4757-4763. PubMed ID: 34845545 [TBL] [Abstract][Full Text] [Related]
9. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240 [TBL] [Abstract][Full Text] [Related]
11. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin. Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381 [TBL] [Abstract][Full Text] [Related]
12. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742 [TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience. Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227 [TBL] [Abstract][Full Text] [Related]
14. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience. Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review. Floriano I; Silvinato A; Reis JC; Cafalli C; Bernardo WM Clinics (Sao Paulo); 2022; 77():100039. PubMed ID: 35576869 [TBL] [Abstract][Full Text] [Related]
16. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856 [TBL] [Abstract][Full Text] [Related]
18. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial? Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032 [TBL] [Abstract][Full Text] [Related]
19. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925 [TBL] [Abstract][Full Text] [Related]
20. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience. Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]